{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-024345","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.219025+00:00","generated_at":"2026-06-06T01:04:12.290354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ironwood reports FY2023 GAAP net loss of $1.0B; LINZESS sales $1.1B (+7%)","bullets":["FY2023 total revenue $442.7M; LINZESS collaboration revenue $430M; Q4 revenue $117.6M.","FY2023 GAAP net loss attributable to Ironwood $1.002B ($6.45 diluted loss/share), vs FY2022 net income $175M.","LINZESS U.S. net sales $1.1B (+7% YoY), prescription demand +10% YoY; pediatric IBS-C approval in June 2023.","Expects topline STARS Phase 3 study of apraglutide in SBS-IF in March 2024; CNP-104 Phase 2 data in Q3 2024.","FY2023 adjusted EBITDA loss $884.8M (includes impairment), vs positive $251.8M in FY2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-024345","json":"https://secwatch.observer/filing/0001104659-24-024345.json","markdown":"https://secwatch.observer/filing/0001104659-24-024345.md","text":"https://secwatch.observer/filing/0001104659-24-024345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/tm246124d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:04:12.290354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0347600a5f311f5ab073986aae02d0787333e0a2","claim":"IRONWOOD PHARMACEUTICALS INC reported the quarter ended December 31, 2023 results: revenue $ 117,553, net income (1,087), EPS (0.01).","evidence_excerpt":"Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$ 117,553"},{"label":"Net income","value":"(1,087)"},{"label":"EPS","value":"(0.01)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"33cec4e72973da042649c914118a3c1ef88f39c3","claim":"IRONWOOD PHARMACEUTICALS INC reported the year ended December 31, 2023 results: revenue $ 442,735, net income (1,002,239), EPS (6.45).","evidence_excerpt":"Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$ 442,735"},{"label":"Net income","value":"(1,002,239)"},{"label":"EPS","value":"(6.45)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}